rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ZNTL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Zentalis at guggenheim conference: azenosertib strategy advances
      Nov 10Investing.comZNTL
      Why is Zentalis Pharmaceuticals stock climbing today?
      Nov 10Investing.comZNTL
      Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
      Nov 9Yahoo FinanceZNTL
      Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
      Nov 3Yahoo FinanceZNTL
      Zentalis reports survival data for ovarian cancer drug trial
      Oct 23Investing.comZNTL
      Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
      Oct 23Yahoo FinanceZNTL
      Zentalis Validates a Multibillion-Dollar Cancer Market as Aprea Therapeutics Emerges as a Next-Generation Contender
      Oct 22BarchartAPREZNTL
      Zentalis Validates a Multibillion-Dollar Cancer Market as Aprea Therapeutics Emerges as a Next-Generation Contender
      Oct 21BarchartAPREZNTL
      Zentalis stock rises on cancer trial data (ZNTL:NASDAQ)
      Oct 19Seeking AlphaZNTL
      H.C. Wainwright reiterates Zentalis stock rating on survival data
      Oct 19Investing.comZNTL
      Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
      Oct 18Yahoo FinanceZNTL
      Zentalis Pharmaceuticals Shares Rise After Leerink Upgrade
      Oct 5Yahoo FinanceZNTL
      Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating

      Zentalis Pharmaceuticals (NASDAQ:ZNTL) shares rose 4. 4% in pre-market trading after Leerink Partners assumed coverage of the biotechnology company with an Outperform rating and an $8 price target.

      Oct 5Yahoo FinanceZNTL
      Why is Zentalis Pharmaceuticals stock up 4% today?
      Oct 5Investing.comZNTL
      Leerink Upgrades Zentalis Pharmaceuticals to Outperform From Market Perform, Price Target is $8
      Oct 5Yahoo FinanceZNTL
      Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 1Yahoo FinanceZNTL
      This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales - Zentalis Pharmaceuticals (NASDA

      William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.

      Sep 16BenzingaZNTL
      This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
      Sep 16BenzingaZNTL
      William Blair Initiates Zentalis Pharmaceuticals at Outperform
      Sep 16Yahoo FinanceZNTL
      William Blair initiates Zentalis stock with outperform rating
      Sep 15Investing.comZNTL
      Zentalis at Morgan Stanley conference: azenosertib push gains shape
      Sep 14Investing.comZNTLMS
      Zentalis at Wells Fargo conference: azenosertib gains clearer path
      Sep 8Investing.comZNTLWFC
      Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

      SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference, Boston, MA. Fireside discussion, September 8, 2026, 4:30p

      Sep 2Yahoo FinanceZNTL
      Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Sep 1Yahoo FinanceZNTL
      Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib (ZNTL)
      Aug 31Seeking AlphaZNTL
      Exclusive BAC Article: Zentalis Pharmaceuticals; DENALI Azenosertib Data PROC 1st Half 2027, MUIR Trial Expansion Results PROC & Beyond, And Catalysts (NASDAQ:ZNTL)
      Aug 26Seeking AlphaZNTL

      This is the newest page. Registered accounts read further back.